|
|
 |
|
Viewing report
|
|
|
|
Complementary and alternative therapies in cancer
Datamonitor, July 2002
Up to 80% of cancer patients have also tried at least one complementary approach. Opportunities exist for pharmaceutical organizations to offer educational programs for physicians and patients, both highlighting possible contraindications for complementary products and the company’s branded products, and to align branded products with potentially synergistic complementary approaches. Scientific investigation of herbal remedies is likely to identify novel pharmacological compounds.A review of commonly used and best-studied vitamin, dietary, herbal and botanical and mind-body approaches to cancerSummaries include clinical data, analysis of the expected efficacy and future potential of these therapiesConfounding factors, such as lack of scientific effect or potentially hazardous side effects, are discussedEstimates of current and future clinical uptake in the US and Europe are presentedComplementary and standard approaches to cancer treatment are compared in a side-by-side overview of ability to meet today’s cancer patients’ needsThe use of complementary therapies is growing and partnering of pharmaceutical agents with traditional therapies is likely to increase the usage of both. Furthermore, increased scientific analysis of complementary and alternative medicines may lead to the identification of novel therapeutic compounds.Understand the future role of regulatory agencies in the incorporation of complementary approaches into routine careExploit co-branding opportunities for conventional pharmacological products with complementary productsIdentify opportunities to align branded products with potentially synergistic complementary approaches
Customers who bought this item also bought
Complementary and Alternative Medicine/'Wellness' Guideline, 2nd Edition - 2009 Update
Complementary and Alternative Medicines in the United States 2008
Complementary Therapies and the Management of Diabetes and Vascular Disease: A Matter of Balance
Market Dynamics 2002: Anti-Cancer Innovatives Series Part III - Gene Therapies
Br Malls Participacoes Sa
Br. Holdings Corporation
NBJ's Complementary and Alternative Medicine and Practitioner Supplement Sales Report 2007
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies
Treatment Algorithms 2001: Venous Thromboembolism - Prophylaxis
BR HOLDINGS - World'Vest Base Dossier
Treatment Algorithms 2001: Lung Cancer
|
|
|
|
